Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Raw defines a TIR-fold cADPR hydrolase cooperating with dSarm in development and axon degeneration.

Cell communication and signaling : CCS·2026
Same author

Dynamics of the SS Loop Regulates SARM1's Catalysis.

ACS chemical neuroscience·2026
Same author

Methodological guidelines for P2X receptor assays and data interpretation.

Cell death & disease·2026
Same author

Targeting purinergic receptors in glioblastoma with nanobody-displaying AAV vectors.

Neuropharmacology·2026
Same author

Structural modeling and functional characterization of a novel gain-of-function TLR8 variant causing severe inflammatory syndrome.

JCI insight·2026
Same author

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing Cells.

Allergy·2026

Related Experiment Video

Updated: Mar 20, 2026

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

12.2K

Immuno-targeting the multifunctional CD38 using nanobody.

Ting Li1, Shali Qi2, Mandy Unger3

  • 1School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

Scientific Reports
|June 3, 2016
PubMed
Summary

Researchers developed nanobodies targeting CD38, a protein highly expressed in multiple myeloma (MM). These nanobodies led to an effective immunotoxin for treating MM cells, showing promise for new therapies and diagnostics.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

12.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • CD38 is a cell surface antigen and signaling enzyme overexpressed in hematologic malignancies like multiple myeloma (MM).
  • CD38's role in calcium signaling and its high expression in MM make it a promising therapeutic target.

Purpose of the Study:

  • To generate high-affinity nanobodies against CD38 for targeted immunotherapy.
  • To develop novel tools for quantifying CD38 expression and create effective anti-MM agents.

Main Methods:

  • Generation and affinity assessment of nanobodies against CD38.
  • Crystal structure determination of CD38-nanobody complexes to identify epitopes.
  • Engineering of chromobodies for CD38 expression analysis.
  • Construction and in vitro testing of a CD38-targeted immunotoxin (nanobody-PE38).

Main Results:

  • High-affinity nanobodies targeting three distinct CD38 epitopes were developed.
  • Chromobodies enabled efficient quantification of CD38 expression, confirming higher levels in MM cells.
  • The nanobody-PE38 immunotoxin demonstrated potent and selective cytotoxicity against MM cells (EC50 ~10^-11 M).
  • Retinoid acid treatment enhanced CD38 expression and immunotoxin efficacy.

Conclusions:

  • Nanobodies are effective tools for targeting CD38 in multiple myeloma.
  • The developed immunotoxin shows significant potential for MM therapy.
  • CD38-targeted strategies, including immunotoxins and expression modulation, offer promising avenues for clinical application and diagnostics.